Yikuai Medicine Secures Tens of Millions in USD in Series B+ Funding to Advance Pharmacy Supply Chain Innovation and Chain Integration

Recently,Pharmacy Operations Service Provider “Yikuai Medicine” Announces Completion of Tens of Millions of USD in Series B+ Financing. This round of financing was led byCBC Group Leads Investment, existing shareholdersQianji CapitalandDuxiu CapitalCo-investment,Probe CapitalAs the exclusive financial advisor.The funds obtained will be used to enhance the overall service level, including operations, technology, and products.

Against the backdrop of China’s healthcare reform, stakeholders across the supply chain—from hospitals to retail outlets—are striving to enhance efficiency and reduce costs. Hunan Wholesale Pharmaceutical Technology Co., Ltd. believes that China’s pharmaceutical retail market will gradually move away from fragmentation toward consolidation through chain operations and centralized integration.Hunan Wholesale Pharmaceutical Technology Co., Ltd. is committed to working with all partners to uphold quality and drive continuous innovation, meeting consumers’ endless pursuit of health and well-being. Meanwhile, by adhering to its core philosophy of delivering specialized, tangible value and providing innovative supply chain services and support, the company empowers the sustained growth of pharmacy chains, making pharmacy operations more efficient and manageable.

As a pharmacy operations service provider,Hunan Wholesale Pharmaceutical Technology Co., Ltd. focuses on growth-oriented pharmacy chains, enhancing their survival and development capabilities during the chain expansion process., to assist clientsResist competitive pressures, increase market share, and improve profitability, contributing our wisdom and strength to the development of the real economy and small and medium-sized enterprises.

Hunan Wholesale Pharmaceutical Technology Co., Ltd. leverages its robust supply chain to help partners build their own private-label brands. To assist clients in alleviating the pressure of homogeneous product competition at the retail level and enhancing their profitability, the company remains committed to quality and innovation. It has developed a series of proprietary brands, including Yuandian, Antaibang, Xinglintai, Fantong, Futai, Shizhenling, Duoweijia, and Bowei, granting clients exclusive regional distribution rights. To date, Hunan Wholesale Pharmaceutical Technology Co., Ltd.Nearly 200 partner manufacturers, with collaborative production relationships established with nearly half of the top 100 pharmaceutical companies.。

“Operational Capabilities, Technological Capabilities, Professional Expertise"Three aspects of capability enhancement services provided by Wholesale Pharmaceutical to its partners,"Provide support for pharmacy management, analysis, operations, and training through an integrated online-to-offline (O2O) solution.。

Over the past year, Hunan Wholesale Pharmaceutical Technology Co., Ltd. has prioritized the development of its PHDS and P4 systems. The PHDS system is a Pharmacy Operation Diagnostic System., leveraging big data to conduct a multi-dimensional assessment of chain management capabilities by focusing on product structure, pricing, inventory management, and data analytics.Help pharmacies promptly identify and understand operational issues, uncover customers' true needs, and thereby optimize their service capabilities.

P4 System Primarily Addresses Pharmacy-Related Talent Issues, thereby optimizing talent empowerment and helping to enhance the professional competence of pharmacy staff. The system provides differentiated training for employees at various levels and in different roles, offering systematic courses through live streaming lectures, group interactions, self-assessment of learning outcomes, and offline mentoring.Hunan Wholesale Pharmaceutical Technology Co., Ltd. leverages this system to transform its expertise in pharmacy operations and pharmaceutical sales into modular, tool-based services, making them easier for clients to understand and master.

Led by a core team of industry veterans and senior experts,Hunan Wholesale Pharmaceutical Technology Co., Ltd. achieved a 300% year-on-year increase in sales revenue in 2021.As of now, the pharmacy operation services of Hunan Wholesale Pharmaceutical Technology Co., Ltd. haveCovering 26 provinces and municipalities across China，Over 50,000 Partner Pharmacy Stores, with sales revenue expected to exceed RMB 500 million in 2022.

Gao Bo, CEO of Hunan Wholesale Pharmaceutical Technology Co., Ltd., stated, the pharmaceutical B2B sector remains a highly promising track,B2B models emerge from the equilibrium of strategic interactions across every link in the industrial chain. Business clients’ purchasing decisions are often extremely rational, making simple transaction-matching insufficient to meet their needs. Only by ensuring sustained profitability for both upstream and downstream partners, while providing robust supply chain, operational, and technical services, can companies establish long-term collaborations with clients. This constitutes the industry’s fundamental barrier to entry.

He Yu, Co-founder and CFO of Hunan Wholesale Pharmaceutical Technology Co., Ltd., mentioned in an interview：“Digital empowerment will undoubtedly remain the core and focus of industry development, both over the past year and in the future."The expansion of the industry scale will inevitably raise demands for cost control and efficiency. Hunan Wholesale Pharmaceutical Technology Co., Ltd. strives to standardize and productize its digital empowerment services as much as possible, helping pharmacies achieve cost reduction, efficiency improvement, and market expansion rapidly during their operations and development."

Marco, Managing Director of CBC Group, stated: China has thousands of pharmaceutical companies and hundreds of thousands of pharmacies, with obvious industry characteristics of congestion at both ends and serious homogenization. Hunan Wholesale Pharmaceutical Technology Co., Ltd. has greatly solved the pain points of inefficient supply chains and high costs through an innovative retail drug supply chain and product system. By leveraging its extensive experience in chain pharmacy management and operations, along with empowerment through digital systems, it has optimized the landscape of China's pharmaceutical retail sector. The highly integrated experience of generic drug manufacturers and pharmacies in developed countries is worth learning from, and Hunan Wholesale Pharmaceutical Technology Co., Ltd. has promoted this trend through its innovative supply chain system, benefiting the entire industry.

For its future 2.0 and 3.0 service versions, Hunan Wholesale Pharmaceutical Technology Co., Ltd. will transcend the functional limitations of single-pharmacy management and operations. Aligning with the broader trend of pharmacy chain integration, the company will introduce tailored service solutions based on pharmacy tier, operational performance, chain scale, and regional policies, thereby reducing operational uncertainties for chain stores and enhancing overall business performance.

Hunan Wholesale Pharmaceutical Technology Co., Ltd. plans to establish a comprehensive pharmacy service operation model by iterating its supply chain products, information services, and operational support, thereby supporting the future transformation of China’s pharmacy sector toward chain-based, centralized, and standardized operations.In the short term, Hunan Wholesale Pharmaceutical Technology Co., Ltd. will continue to develop systematic service solutions to provide in-depth services to clients, further expand its coverage of high-growth pharmacy chains across China, while enhancing and upgrading the PDHS and P4 systems and expanding its supply chain network.

CBC Group is the largest healthcare investment group in Asia, dedicated to value creation and global resource integration. Leveraging a network of top-tier global scientists and entrepreneurs, CBC Group is committed to enhancing efficiency and leading innovation. It consistently explores and implements its unique active investment model, which is driven by operations, platforms, and global resource mobilization. The firm has spearheaded the establishment of more than ten leading healthcare companies, directly engaging in value creation through an “investor-plus-entrepreneur” approach to deliver more inclusive healthcare services and address the growing unmet medical needs worldwide. Founded in 2014, CBC Group boasts a strong professional team specializing in investment, the healthcare industry, and post-investment management. Headquartered in Singapore, with offices in Shanghai, Hong Kong, New York, Boston, San Diego, Tokyo, and Beijing, the firm focuses on growth-oriented opportunities in multiple core areas of the healthcare sector, including platform development, acquisitions, and credit investments.

CBC Growth Fund, established by CBC Group, has consistently focused on high-value, high-potential projects in the healthcare sector since its inception. The fund prioritizes equity investments in biopharmaceuticals, medical devices, digital health, and emerging healthcare technologies, targeting primarily early-stage and growth-stage companies. Leveraging CBC Group’s robust financial strength, global resources, and comprehensive “investment plus operations” expertise, the Growth Fund team places particular emphasis on serial entrepreneurs with strong scientific backgrounds and extensive industry experience. It prioritizes high-quality ventures with the potential to become global industry leaders and occupy frontier market positions.